The goal of this clinical research study is to find the highest tolerable dose of vemurafenib
that can be given in combination with either everolimus or temsirolimus. The safety of these
drug combinations will also be studied.
Vemurafenib is designed to block BRAF inside the cancer cells, which is a mutation that is
involved in cancer cell growth.
Temsirolimus and everolimus are designed to block the growth of cancer cells, which may cause
cancer cells to die.